ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Impact of baseline hypoalbuminemia on peripheral edema induced by gemcitabine and nab-paclitaxel for pancreatic cancer treatment.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Going beyond total skeletal muscle area at L3 (tSMA) to accurately assess pancreatic cancer cachexia.Journal of gastrointestinal oncology · 2026Article
- Pancreatic ductal adenocarcinoma and edema: reassessing cachexia markers.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGemcitabine (GEM) + nanoparticle albumin-bound paclitaxel (nab-PTX), which is effective in treating pancreatic cancer, frequently induces peripheral edema. Hypoalbuminemia causes generalized peripheral edema and occasionally occurs in patients with cancer, but reports evaluating its interaction with chemotherapy-induced symptoms are lacking. Therefore, we aimed to assess the effect of baseline hypoalbuminemia on peripheral edema following real-world GEM + nab-PTX therapy.
methodsPatients with pancreatic cancer receiving GEM + nab-PTX (n = 212) were divided into a hypoalbuminemia group (serum albumin levels < 3.5 g/dL), and a control group without hypoalbuminemia, and retrospectively evaluated. The primary endpoint was the incidence of grade ≥ 2 peripheral edema within 6 months of treatment initiation.
resultsThe incidence of grade ≥ 2 peripheral edema within 6 months was 5.7% in the control group and 22.6% in the hypoalbuminemia group, with a significant difference (P = 0.0009), meeting the primary endpoint. The onset time of grade ≥ 2 peripheral edema was significantly earlier in the hypoalbuminemia group than in the control group (P = 0.0003). In contrast, the incidence of all-grade symptoms was 20.1% in the control group and 30.2% in the hypoalbuminemia group, which was not significantly different (P = 0.13). These results were confirmed in the propensity score-matched population. Multivariate Cox proportional hazard regression analyses showed that baseline hypoalbuminemia was a significant risk factor for grade ≥ 2 peripheral edema (adjusted hazard ratio, 3.84; 95% confidence interval, 1.60-9.23; P = 0.003).
conclusionOur study revealed that patients with baseline hypoalbuminemia who received GEM + nab-PTX therapy for pancreatic cancer developed problematic peripheral edema.
Indexed as
Identifiers
41082007What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.